Cardiovascular Disease in Systemic Lupus Erythematosus: recent data on epidemiology, risk factors and prevention.
CONCLUSION: SLE patients warrant regular assessment of their cardiovascular risk with prompt initiation of general and disease-specific risk-lowering strategies. Other: Further studies will be required regarding the use of non-invasive tools and biomarkers for cardiovascular assessment and of risk-lowering strategies tailored to SLE patients.
PMID: 31880245 [PubMed - as supplied by publisher]
Source: Current Vascular Pharmacology - Category: Drugs & Pharmacology Authors: Kostopoulou M, Nikolopoulos D, Parodis I, Bertsias G Tags: Curr Vasc Pharmacol Source Type: research
More News: Antiphospholipid Syndrome | Aspirin | Cardiology | Cardiovascular | Cholesterol | Drugs & Pharmacology | Epidemiology | Heart | Hughes Syndrome | Hydroxychloroquine | Lupus | Prednisone | Rheumatology | Smokers | Statin Therapy | Study